Skip to content

The Value of MRI in Assessing the Status of Retroperitoneal Resection Margin in Colon Cancer

To Explore the Value of Colon MRI in Assessing the Status of Retroperitoneal Resection Margin Following Beyond Complete Mesocolic Excision Surgery for Advanced Colon Cancer

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05859581
Enrollment
29
Registered
2023-05-16
Start date
2023-04-02
Completion date
2023-08-31
Last updated
2023-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon Cancer

Keywords

Colon cancer, MRI, Resection margin

Brief summary

The goal of this clinical trial is to explore the value of colon MRI in assessing the status of retroperitoneal resection margin (RPRM) for advanced colon cancer. The main questions it aims to answer are: * Concordance between MRI suspected RPRM positive and pathologically confirmed positive. * Can RPRM-positive patients undergo beyond complete mesocolic excision (CME) surgery in order to achieve R0 resection? Participants will undergo colon MRI examination and once MRI suspects RPRM positive, they will receive beyond CME surgery.

Interventions

PROCEDUREBeyond complete mesocolic excision surgery

If the participants were diagnosed with positive retroperitoneal resection margin (RPRM), they underwent beyond complete mesocolic excision surgery to ensure the R0 resection.

Sponsors

Peking University Cancer Hospital & Institute
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* primary colon adenocarcinoma confirmed by biopsy * preoperative CT suspecting retroperitoneal resection margin (RPRM) positive * received colon MRI scan * underwent beyond complete mesocolic excision surgery * sufficient clinical and pathological results

Exclusion criteria

* combined with other malignant tumors * simultaneous distant metastasis * definite invaded other organs or structures (T4b tumors)

Design outcomes

Primary

MeasureTime frameDescription
Coincidence rate with pathological resultwithin 2 weeks after surgeryCoincidence rate between MRI diagnosed retroperitoneal resection margin and pathologically confirmed positive

Countries

China

Contacts

Primary ContactZhen Guan, MD
18801231091@163.com861088196825

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026